The medical device maker said new investor J.P. Morgan Life Sciences Private Capital led the oversubscribed Series D, which also had participation from existing funders. (The Logic)
The medical device maker said new investor J.P. Morgan Life Sciences Private Capital led the oversubscribed Series D, which also had participation from existing funders. (The Logic)
The medical device maker said new investor J.P. Morgan Life Sciences Private Capital led the oversubscribed Series D, which also had participation from existing funders. (The Logic)
Talking point: ABK, which has raised nearly US$122 million to date, was valued at US$73 million after its Series C, according to PitchBook. The money will fund clinical operations, research and development, and the commercialization of its Eye90 microspheres—a technology used to help treat some cancerous tumours. It has so far only been used in clinical trials. The funds from this round will also help ABK expand its manufacturing and supply chain operations. The firm currently has a facility in Halifax.
Loading...
You have shared 5 articles this month and reached the maximum amount of shares available.
CloseIf you would like to purchase a sharing license please contact The Logic support at [email protected].
CloseYou have gifted 0 article(s) this month and have 5 remaining.
Recipients will be able to read the full text of the article after submitting their email address. They will not have access to other articles or subscriber benefits.
Get up to speed in minutes with insights and analysis on the most important stories of the day, every weekday.
See the bigger picture with reporters and industry experts in subscriber-exclusive events.
Membership provides access to our popular Slack channel, participation in subscriber surveys and invitations to exclusive events with our journalists and special guests.